94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Mehran Rahimlou1,2
Shima Nematollahi1Durdana Husain1Nasrin Banaei-Jahromi3Nastaran Majdinasab4
Seyed Ahmad Hosseini1*- 1Nutrition and Metabolic Disease Research Center, Clinical Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
- 2Department of Nutrition, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
- 3Department of Nutrition, School of Allied Medical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
- 4Department of Neurology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
A corrigendum on
Probiotic supplementation and systemic inflammation in relapsing-remitting multiple sclerosis: A randomized, double-blind, placebo-controlled trial
by Rahimlou, M., Nematollahi, S., Husain, D., Banaei-Jahromi, N., Majdinasab, N., and Hosseini, S. A. (2022). Front. Neurosci. 16:901846. doi: 10.3389/fnins.2022.901846
In the published article, there was an error in affiliation 1 as published. Instead of “1 Department of Nutrition, School of Allied Medical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran,” it should be “1 Nutrition and Metabolic Disease Research Center, Clinical Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.”
In addition, there was an error in the affiliations for Nasrin Banaei-Jahromi. Instead of “1 Department of Nutrition, School of Allied Medical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran,” it should be “3 Department of Nutrition, School of Allied Medical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: probiotic, multiple sclerosis, inflammation, clinical trial, gut microbiome
Citation: Rahimlou M, Nematollahi S, Husain D, Banaei-Jahromi N, Majdinasab N and Hosseini SA (2022) Corrigendum: Probiotic supplementation and systemic inflammation in relapsing-remitting multiple sclerosis: A randomized, double-blind, placebo-controlled trial. Front. Neurosci. 16:1085572. doi: 10.3389/fnins.2022.1085572
Received: 31 October 2022; Accepted: 01 November 2022;
Published: 15 November 2022.
Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
Copyright © 2022 Rahimlou, Nematollahi, Husain, Banaei-Jahromi, Majdinasab and Hosseini. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Seyed Ahmad Hosseini, c2V5ZWRhaG1hZGhvc3NlaW5pQHlhaG9vLmNvbQ==; c2V5ZWRhaG1hZGhvc3NlaW5paTIwQGdtYWlsLmNvbQ==